Why the study?
Substrate-based ablation for VT using Ripple map is effective in ischemic cardiomyopathy, but its feasibility and effectiveness had yet to be evaluated in patients with nonischemic cardiomyopathy.
Does substrate-based ablation using Ripple mapping improve freedom from ventricular tachycardia in patients with nonischemic cardiomyopathy?
Does substrate-based ablation using Ripple mapping improve freedom from ventricular tachycardia in patients with nonischemic cardiomyopathy?
Ripple mapping-based substrate ablation is feasible in patients with nonischemic cardiomyopathy, and targeting ablation closer to Ripple channels is associated with greater freedom from VT recurrence.
May support Ripple channel targeting in nonischemic cardiomyopathy VT ablation; hypothesis-generating and requires randomized confirmation before practice change.
INTRODUCTION: Substrate-based ablation for ventricular tachycardia (VT) using Ripple map (RM) is an effective treatment strategy for patients with ischemic cardiomyopathy but has yet to be evaluated in patients with nonischemic cardiomyopathy (NICMO). The aim of this study is to determine the feasibility and effectiveness of an RM-based ablation for NICMO patients. METHODS AND RESULTS: This was a single-center, retrospective study including all NICMO patients undergoing VT ablation at St Vincent Hospital between January 1, 2018 and January 12, 2019. Retrospective RM analysis was performed on those that had a substrate-based ablation to identify the location and number of Ripple channels as well as their proximity to ablation lesions. Thirty-three patients met the inclusion criteria and had a median age of 65 (58, 73.5) with 15.2% of the population being female, and were followed for a median duration of 451 (217.5, 586.5) days. Of these patients, 23 (69.7%) had a substrate-based ablation with a median procedural duration of 196.4 (186.8, 339) min, 1946 (517, 2750) points collected per map, and 277 (141, 554) points were within the scar. Two (8.6%) procedural complications occurred, and 7 (30.4%) patients had VT recurrence during follow-up. RM analysis revealed an average of two Ripple channels and the patients without VT recurrence had ablation performed closer to the Ripple channels: 0 (0, 4.7) versus 14.3 (0, 23.5) cm; p = .02. CONCLUSION: An RM-based substrate ablation can be performed in NICMO patients and ablation within Ripple channels is a predictor of VT freedom.
No takes yet. Share an insight, caveat, or question.
Gilge et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: